Recent Analysts’ Ratings Changes for Corcept Therapeutics (CORT)

Corcept Therapeutics (NASDAQ: CORT) recently received a number of ratings updates from brokerages and research firms:

• 8/1/2026 – Corcept Therapeutics was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 7/30/2026 – Corcept Therapeutics had its price target raised by HC Wainwright from $95.00 to $165.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Corcept Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock, up from $88.00.
• 7/29/2026 – Corcept Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $135.00 to $150.00. They now have a “buy” rating on the stock.
• 7/27/2026 – Corcept Therapeutics was downgraded by Wolfe Research from “peer perform” to “underperform”. They now have a $50.00 price target on the stock.
• 6/24/2026 – Corcept Therapeutics had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 6/15/2026 – Corcept Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.

Insider Transactions at Corcept Therapeutics

In other news, CFO Atabak Mokari sold 80,000 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $114.71, for a total value of $9,176,800.00. Following the completion of the sale, the chief financial officer owned 16,130 shares of the company’s stock, valued at approximately $1,850,272.30. This represents a 83.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Guyer sold 16,300 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $113.43, for a total transaction of $1,848,909.00. Following the completion of the sale, the insider directly owned 3,985 shares of the company’s stock, valued at $452,018.55. This trade represents a 80.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 402,876 shares of company stock worth $35,118,563. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.